Shinpoong Pharmaceutical Co (019170) Fair Value & Analysis
Healthcare · KR · Market cap 424B KRW
Fair value as of: Jul 24, 2026
From 24 valuation models · updated 17 days ago
Share price +9.8% over the past month.
A solid business, but screening 58% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (4,693 KRW). The favourable scenario is already priced in.
- Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.
How to read this chart
60‑month range 6,650 KRW – 113,647 KRW · fair‑value band 2,816 KRW – 4,693 KRW · the 8,890 KRW price screens above the 3,755 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 24, 2026.
Analysis
Shinpoong Pharmaceutical Co (019170) currently trades at 8,890 KRW, while our model-based Fair Value estimate is 3,755 KRW, implying the stock looks roughly 57.8% overvalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Shinpoong Pharmaceutical Co generated revenue of 234B KRW at a net margin of 4.5%. Revenue declined 1.6% year over year. It earns a return on equity of 3.7%. Net debt stands at 7.5B KRW. Fundamentals as of Jul 24, 2026
Our scenario range runs from 2,816 KRW (bear case) to 4,693 KRW (bull case); at 8,890 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 57% below its 52-week high and 13% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -58%, 019170 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (4,394 KRW) versus Dividend Discount (1,225 KRW). Highest evidence: Growth DCF (80).
Notify me when 019170 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 24, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 13
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics.
Full company description
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; and drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; prescription drugs; wound dressings; health functional food; and over the counter products. In addition, the company engages in business management and exports its products to approximately 50 countries. The company was founded in 1962 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shinpoong Pharmaceutical Co reported revenue of 235B KRW in FY2025 versus 189B KRW in FY2021, a compound +5.5%/yr. Reported net income was 8.8B KRW in FY2025.
019170 screens 58% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 624 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Shinpoong Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shinpoong Pharmaceutical Co (019170) overvalued or undervalued?
What is the fair value of 019170?
What is the quality score of 019170?
What is the revenue of Shinpoong Pharmaceutical Co (019170)?
What is the net profit margin of 019170?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shinpoong Pharmaceutical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.